Biotheus Inc. clinical trials
Acquired by BioNTech SE, Feb 3, 2025 · source ↗
The registry lists 18 studies whose lead sponsor is Biotheus Inc.. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Before and after it joined BioNTech SE
- First submitted before Biotheus Inc. became part of BioNTech SE
- 17
- First submitted after Biotheus Inc. became part of BioNTech SE
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Where
- China
- 16
Registry sponsor names on this page
- Biotheus Inc.18 studies
Something wrong with this grouping? Tell us on the BioNTech SE page.
Studies
Recruiting first, then most recently updated. Showing 18 of 18. All BioNTech SE studies →
- PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerRecruitingNCT07133750Phase 2
Sponsor listed in the registry: Biotheus Inc. · First submitted after Biotheus Inc. became part of BioNTech SE
- A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCNot yet recruitingNCT06584071Phase 1/2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- PM8002 in the Treatment of Patients With Advanced Solid TumorsRecruitingNCT05918445Phase 1/2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM1015 in Patients With Advanced Solid TumorsRecruitingNCT05950815Phase 1
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM1022 in Patients With Advanced TumorsRecruitingNCT05867771Phase 1/2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid TumorsRecruitingNCT05862831Phase 1/2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid TumorsRecruitingNCT05839106Phase 1/2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid TumoursNot yet recruitingNCT05537051Phase 1
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerActive, not recruitingNCT06616532Phase 3
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCActive, not recruitingNCT06419621Phase 3
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM8002 in Combination With Chemotherapy in Patients With NENActive, not recruitingNCT05879055Phase 2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Phase 2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPMCompletedNCT05918107Phase 2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLCActive, not recruitingNCT05756972Phase 2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCActive, not recruitingNCT05844150Phase 2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBCActive, not recruitingNCT05918133Phase 1/2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM8002 in Combination With Chemotherapy in Patients With SCLCActive, not recruitingNCT05879068Phase 2
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE
- A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced TumoursStatus unknownNCT05607563Phase 1
Sponsor listed in the registry: Biotheus Inc. · First submitted before Biotheus Inc. became part of BioNTech SE